The Rouen, France-based company said its second-generation robotic system integrates capabilities designed to meet the increasing demands of complex coronary procedures. It develops robotic solutions that utilize bionic technology aimed at optimizing the safety of robotic-assisted coronary angioplasty.
Robocath’s procedure revascularizes the cardiac muscle through the implantation of one or more stents to arteries supplying blood. It designed its robotic technologies to operate with precision and perform accurate movements to create better interventional conditions. The company has CE mark and other regulatory approvals for its first robotic solution, the R-One system, currently used in Europe, Africa and China.
For its second-generation robot, the company said it utilized clinical and technological experience gained through R-One.
The study will recruit 20 patients with coronary artery disease, the company said. Primarily, it plans to evaluate complex cases representative of the routine activity of a catheterization laboratory. The study will take place at the Centre Cardiologique du Nord (CCN) in Saint-Denis, France.
“The launch of this first-in-human study represents a major milestone for Robocath,” said Robocath President Philippe Bencteux. “With our second-generation robot we are leveraging the strong clinical and industrial experience acquired with our first platform, now in use internationally. This world first illustrates our leadership position and our commitment to continuing to push the boundaries of interventional robotic technology.”
